Dexamethasone prodrug emulsion

Drug Profile

Dexamethasone prodrug emulsion

Alternative Names: Cortiject; Dexamethasone palmitate intravitreal injection; Nova 63035; NOVA63035; Ophthalmic corticosteroid prodrug - Santen SAS

Latest Information Update: 12 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novagali Pharma
  • Developer Santen S.A.S.
  • Class Corticosteroids; Eye disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic macular oedema

Most Recent Events

  • 24 Sep 2015 Phase I/II development is ongoing in the USA
  • 08 May 2013 Novagali Pharma SAS is now called Santen SAS
  • 07 Feb 2012 Phase-I/II clinical trials in Diabetic macular oedema in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top